ReVenG: Retreatment with venetoclax plus obinutuzumab in patients with relapsed CLL
Venetoclax plus obinutuzumab has proved to be effective as frontline therapy in patients with Chronic Lymphocytic Leukemia (CLL). In this MEDtalk, Matthew S. Davids presents a trial-in-progress, investigating retreatment responses with venetoclax plus obinutuzumab in patients with relapsed CLL. Matthew is hoping for the results to support a future retreatment regimen for this group of patients.
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.